Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of \u00a37,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.
Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford\u2019s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Jun\u00edn virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
The University of Oxford\u2019s commitment to tackling major global health challenges has been strengthened following the endowment of a chair in global health and clinical development. The new permanent post was made possible by a \u00a35 million donation from Brazilian healthcare organisation SAIL for Health.
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
Dr Parvinder Aley, Director of Global Operations at the Oxford Vaccine Group, has been recognised and celebrated in the 2023 King\u2019s Birthday Honours list. Dr Aley has been appointed an Officer of the Order of the British Empire (OBE) for services to vaccination during the COVID-19 pandemic.
Oxford Vaccine Group and Pandemic Sciences Institute\u2019s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.
Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.
More than 40,000 doses of Oxford\u2019s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.
Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children\u2019s Hospital and Vice Master of St Cross College, Oxford.
![\"\"](\"https://www.ovg.ox.ac.uk/news/first-in-human-vaccine-trial-for-nipah-virus/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n